Jason Helfstein, Oppenheimer head of internet research, joins 'The Exchange' to discuss Spotify as the stock sinks on Q2 ...

Trump's trade deals with the EU and Japan pave the way for the stock market to end with it's third straight annual gain of ...

Fintel reports that on July 29, 2025, Oppenheimer upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Sarepta Therapeutics ( NASDAQ: SRPT) was upgraded to Neutral from Underweight at J.P. Morgan as it sees FDA's Elevidys hold removal recommendation in ambulatory patients as a clear win.

Carvana Co. (NYSE:CVNA) is one of the best multibagger stocks according to hedge funds. On July 25, 2025, Oppenheimer analyst ...

Jensen Huang believes questions of whether artificial intelligence (AI) could destroy humanity are fear-mongering — and get ...

Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug ...

Visa and Mastercard are expected to report higher quarterly profits this week on steady consumer spending, and analysts will ...

Oppenheimer made a gutsy, prescient call last year when he warned that US stocks were starting to look too expensive and ...

Sarepta stock sees upgrades and price hikes as analysts reassess Elevidys prospects following a favorable FDA development.

This isn’t a generic re-run. These screenings are a testament to Nolan’s continued support for the IMAX format and enable ...